logo
Acquiring an H in MDS
Lymphadenopathy in a patient with chronic myeloid leukaemia
Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options
Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches
Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities
TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms – a multicentric study on 529 patients
Impact of socioeconomic status on disease phenotype, genomic landscape and outcomes in myelodysplastic syndromes
Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation
Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy – SAKK 38/08
Sphingosine-1-phosphate receptor 1 as a prognostic biomarker and therapeutic target for patients with primary testicular diffuse large B-cell lymphoma
Cell cycle status in AML blast cells from peripheral blood, bone marrow aspirates and trephines and implications for biological studies and treatment
Incidence and risk factors for Central Nervous System thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study
The genetic landscape of paediatric de novo acute myeloid leukaemia as defined by single nucleotide polymorphism array and exon sequencing of 100 candidate genes
Pregnancy loss and risk of ischaemic stroke and myocardial infarction
Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia
To maintain or not, that is the question
A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma
Establishing sickle cell diagnostics and characterizing a paediatric sickle cell disease cohort in Malawi
A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for IGHV-D-J rearrangements and BRAF -V600E mutation: lack of evidence for a common origin
Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma
Corrigendum
Corrigendum